O	0	8	Subgroup
O	9	16	effects
O	17	19	in
O	20	21	a
O	22	32	randomised
O	33	38	trial
O	39	41	of
O	42	51	different
O	52	57	types
O	58	61	and
O	62	67	doses
O	68	70	of
B-intervention	71	79	exercise
O	80	86	during
O	87	93	breast
O	94	100	cancer
O	101	113	chemotherapy
O	113	114	.

O	115	118	The
O	119	127	Combined
O	128	135	Aerobic
O	136	139	and
O	140	150	Resistance
O	151	159	Exercise
O	160	165	Trial
O	166	172	tested
O	173	182	different
O	183	188	types
O	189	192	and
O	193	198	doses
O	199	201	of
O	202	210	exercise
O	211	213	in
O	214	220	breast
O	221	227	cancer
O	228	236	patients
O	237	246	receiving
O	247	259	chemotherapy
O	259	260	.

O	261	265	Here
O	265	266	,
O	267	269	we
O	270	277	explore
O	278	287	potential
O	288	298	moderators
O	299	301	of
O	302	305	the
O	306	314	exercise
O	315	323	training
O	324	333	responses
O	333	334	.

B-eligibility	335	341	Breast
I-eligibility	342	348	cancer
I-eligibility	349	357	patients
I-eligibility	358	368	initiating
I-eligibility	369	381	chemotherapy
O	382	383	(
O	383	384	N
O	384	385	=
B-total-participants	385	388	301
O	388	389	)
O	390	394	were
O	395	403	randomly
O	404	412	assigned
O	413	415	to
O	416	421	three
O	422	427	times
O	428	429	a
O	430	434	week
O	434	435	,
O	436	446	supervised
O	447	455	exercise
O	456	458	of
O	459	460	a
B-control	461	469	standard
I-control	470	474	dose
O	475	477	of
O	478	480	25
O	480	481	-
O	481	483	30
O	484	487	min
O	488	490	of
O	491	498	aerobic
O	499	507	exercise
O	507	508	,
O	509	510	a
O	511	517	higher
O	518	522	dose
O	523	525	of
O	526	528	50
O	528	529	-
O	529	531	60
O	532	535	min
O	536	538	of
O	539	546	aerobic
O	547	555	exercise
O	555	556	,
O	557	559	or
O	560	561	a
O	562	568	higher
O	569	573	dose
O	574	576	of
O	577	579	50
O	579	580	-
O	580	582	60
O	583	586	min
O	587	589	of
O	590	598	combined
O	599	606	aerobic
O	607	610	and
O	611	621	resistance
O	622	630	exercise
O	630	631	.

O	632	640	Outcomes
O	641	645	were
O	646	653	patient
O	653	654	-
O	654	662	reported
O	663	671	symptoms
O	672	675	and
O	676	682	health
O	682	683	-
O	683	690	related
O	691	698	fitness
O	698	699	.

O	700	710	Moderators
O	711	715	were
O	716	724	baseline
O	725	736	demographic
O	736	737	,
O	738	746	exercise
O	746	747	/
O	747	754	fitness
O	754	755	,
O	756	759	and
O	760	766	cancer
O	767	776	variables
O	776	777	.

O	778	782	Body
O	783	787	mass
O	788	793	index
O	794	803	moderated
O	804	807	the
O	808	815	effects
O	816	818	of
O	819	822	the
O	823	831	exercise
O	832	845	interventions
O	846	848	on
B-outcome	849	855	bodily
I-outcome	856	860	pain
O	861	862	(
O	862	863	P
O	864	867	for
O	868	879	interaction
O	879	880	=
O	880	881	0
O	881	882	.
O	882	885	038
O	885	886	)
O	886	887	,
B-outcome	888	897	endocrine
I-outcome	898	906	symptoms
O	907	908	(
O	908	909	P
O	910	913	for
O	914	925	interaction
O	925	926	=
O	926	927	0
O	927	928	.
O	928	931	029
O	931	932	)
O	932	933	,
B-outcome	934	940	taxane
I-outcome	940	941	/
I-outcome	941	951	neuropathy
I-outcome	952	960	symptoms
O	961	962	(
O	962	963	P
O	964	967	for
O	968	979	interaction
O	979	980	=
O	980	981	0
O	981	982	.
O	982	985	013
O	985	986	)
O	986	987	,
B-outcome	988	995	aerobic
I-outcome	996	1003	fitness
O	1004	1005	(
O	1005	1006	P
O	1007	1010	for
O	1011	1022	interaction
O	1022	1023	=
O	1023	1024	0
O	1024	1025	.
O	1025	1028	041
O	1028	1029	)
O	1029	1030	,
B-outcome	1031	1039	muscular
I-outcome	1040	1048	strength
O	1049	1050	(
O	1050	1051	P
O	1052	1055	for
O	1056	1067	interaction
O	1067	1068	=
O	1068	1069	0
O	1069	1070	.
O	1070	1073	007
O	1073	1074	)
O	1074	1075	,
O	1076	1079	and
B-outcome	1080	1083	fat
I-outcome	1084	1088	mass
O	1089	1090	(
O	1090	1091	P
O	1092	1095	for
O	1096	1107	interaction
O	1107	1108	=
O	1108	1109	0
O	1109	1110	.
O	1110	1113	005
O	1113	1114	)
O	1114	1115	.

O	1116	1118	In
O	1119	1126	general
O	1126	1127	,
O	1128	1135	healthy
O	1136	1142	weight
O	1143	1151	patients
O	1152	1161	responded
O	1162	1168	better
O	1169	1171	to
O	1172	1175	the
O	1176	1182	higher
O	1182	1183	-
O	1183	1187	dose
O	1188	1196	exercise
O	1197	1210	interventions
O	1211	1215	than
O	1216	1226	overweight
O	1226	1227	/
O	1227	1232	obese
O	1233	1241	patients
O	1241	1242	.

O	1243	1253	Menopausal
O	1254	1260	status
O	1260	1261	,
O	1262	1265	age
O	1265	1266	,
O	1267	1270	and
O	1271	1279	baseline
O	1280	1287	fitness
O	1288	1297	moderated
O	1298	1301	the
O	1302	1309	effects
O	1310	1312	on
O	1313	1320	patient
O	1320	1321	-
O	1321	1329	reported
O	1330	1338	symptoms
O	1338	1339	.

O	1340	1353	Premenopausal
O	1353	1354	,
O	1355	1362	younger
O	1362	1363	,
O	1364	1367	and
O	1368	1374	fitter
O	1375	1383	patients
O	1384	1392	achieved
O	1393	1400	greater
O	1401	1409	benefits
O	1410	1414	from
O	1415	1418	the
O	1419	1425	higher
O	1425	1426	-
O	1426	1430	dose
O	1431	1439	exercise
O	1440	1453	interventions
O	1453	1454	.

O	1455	1462	Healthy
O	1463	1469	weight
O	1469	1470	,
O	1471	1477	fitter
O	1477	1478	,
O	1479	1482	and
O	1483	1496	premenopausal
O	1496	1497	/
O	1497	1504	younger
O	1505	1511	breast
O	1512	1518	cancer
O	1519	1527	patients
O	1528	1537	receiving
O	1538	1550	chemotherapy
O	1551	1554	are
O	1555	1559	more
O	1560	1566	likely
O	1567	1569	to
O	1570	1577	benefit
O	1578	1582	from
O	1583	1589	higher
O	1589	1590	-
O	1590	1594	dose
O	1595	1603	exercise
O	1604	1617	interventions
O	1617	1618	.
